Journal of pediatric hematology/oncology
-
J. Pediatr. Hematol. Oncol. · Dec 2011
Randomized Controlled Trial Multicenter Study Comparative StudyPolyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Administration of L-asparaginase is limited by hypersensitivity reactions mediated by anti-asparaginase antibodies. To overcome this problem, native Escherichia coli L-asparaginase was conjugated to polyethylene glycol (PEG) to formulate PEG-L-asparaginase, a preparation with decreased immunogenicity and increased circulating half-life. In early trials, PEG-L-asparaginase was tolerated by patients known to be hypersensitive to the native E. coli product. ⋯ PEG asparaginase is a useful agent in patients with allergic reactions to native asparaginase.